68Ga-F(ab')2-trastuzumab fragments

N/A

Report date: 2025/10/20 14:18:09

NME

Base Information

Drug Name68Ga-F(ab')2-trastuzumab fragments

Drug Alias NameGa-68 Labeled F(ab') 2- Trastuzumab

ClassificationRadiation-emitting products > Nuclides > Gallium > 68GaRadiation-emitting products > Radioactive diagnostic agentRadiation-emitting products > Radionuclide Drug Conjugates

Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 binders

TargetsReceptor protein-tyrosine kinase erbB-2

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesMemorial Sloan Kettering Cancer Center

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesMemorial Sloan Kettering Cancer Center

Active IndicationsN/A

Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A